Compare ABRDN Physical Gold Shares ETF (SGOL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ABRDN Physical Gold Shares ETF trades at $42.08, while State Street SPDR S&P Biotech ETF trades at $160. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| SGOL | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $51.41 | $169.55 |
52-Week Low | $34.68 | $93.43 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL is trading at $41.48, down 1.78% with a bearish technical outlook as moving averages signal selling pressure. The stock faces resistance at $42 with support at $41, while RSI indicators show mixed signals. Recent news highlights institutional optimism for gold's medium-term prospects despite near-term volatility, with Goldman Sachs forecasting $4,900/oz gold by year-end.
The outlook remains cautiously optimistic as gold benefits from macroeconomic support including debt concerns and central bank demand. Key risks include Fed policy uncertainty and dollar strength, while technical weakness suggests potential for further consolidation before sustained upward movement.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
